PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|March 17, 2020
Complex Liquid Formulations: Solutions for Scale-Up Challenges
Author(s)Catalent
Complex liquids can be problematic for scale-up and manufacture. Learn how the experts at Catalent have found solutions for the most challenging liquid formulations. Live: Tuesday, Mar. 17, 2020 at 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Mar. 17, 2021 Register free
Register free:
Event Overview:
Scaling-up liquid formulations can present a number of challenges and headaches. This is especially true for complex solutions, suspensions and emulsions as well as biologics, sterile products, potent compounds and sensitive APIs. In this webcast, learn about potential formulation and filling issues when transitioning a liquid formulation from feasibility through commercialization.
Product development experts share insights on a variety of formulation issues including mixing, solubility, microfluidization, viscosity, filtration and special API handling, with discussed solutions based on Catalent’s expertise in complex formulation. Equipment for liquid-filling and scale-up will be discussed with a focus on potential applications of advanced aseptic Blow-Fill-Seal (BFS) technology.
Register early and submit your question for the Q&A discussion.
Key Learning Objectives:
- How to manage challenges associated with typical liquid formulations, as well as unique issues for complex solutions, suspensions, and emulsions
- Special considerations for biologics, as well as potent or sensitive APIs
- Challenges when transitioning from small- to large-scale, and solutions made possible by Blow-Fill-Seal technology
Speakers: Waiken Wong, PhD, Manager, Product Development Engineering, Catalent
Wendy Khine, Director, Project Management, Catalent
Time and date: Tuesday, Mar. 17, 2020 at 1pm EDT | 12pm CDT | 10am PDT
On demand available after airing until Mar. 17, 2021
Sponsor: Catalent
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.